Table 3.

MACE at 30 days after PCI in the Danlou Tablet and placebo groups.

	Incidence		Treatment difference (%)
	Danlou Tablet group	Placebo group	Differencea of incidence (95% CI)	p value
Full-analysis set	N = 109	N = 110
Total MACE, n (%)	24 (22.0)	37 (33.6)	1.8 (1.0, 3.3)	0.06c
Cardiac death, n (%)	0	0
Nonfatal MI, n (%)	24 (22.0)	37 (33.6)	1.8 (1.0, 3.3)	0.06c
Target vessel revascularization, n (%)	0	1 (0.9)		1.0d
Rehospitalization due to CVEb, n (%)	0	0
Per-protocol analysis set	N = 107	N = 109
Total MACE, n (%)	24 (22.4)	36 (33.0)	1.7 (0.9, 3.1)	0.08c
Cardiac death, n (%)	0 (0)	0 (0)
Nonfatal myocardial infarction, n (%)	24 (22.4)	36 (33.0)	1.7 (0.9, 3.1)	0.08c
Target vessel revascularization, n (%)	0	1 (0.9)		1.0d
Rehospitalization due to CVEb, n (%)	0	0

CI, confidence interval; CVE, cardiovascular events; MACE, major adverse cardiac event; and MI, myocardial infarction.

^aDifference of incidence = Danlou Tablet − placebo.

^bCardiovascular events included severe angina or heart failure (NYHF ⩾ IV).

^c p value is from the continuity-adjusted Chi-square test.

^d p value is from Fisher's exact test.